Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Benztropine
Quick Facts
- Generic Name
- Benztropine
- Brand Names
- Cogentin
- Drug Class
- Anticholinergic
- FDA Approved
- 1954
How It Works
Benztropine is an anticholinergic medication that combines muscarinic receptor antagonism with antihistaminic (H1 receptor) properties. Like trihexyphenidyl, it works by blocking acetylcholine receptors in the central nervous system to restore the dopamine-acetylcholine balance disrupted in Parkinson's disease. The additional antihistaminic activity may contribute to its sedating effects and its occasional use for drooling (sialorrhea) in PD.
What to Expect as a Patient
Benztropine works similarly to trihexyphenidyl for tremor, but its additional antihistaminic properties make it more sedating. This can be a disadvantage during the day but may help if you take it at bedtime. Side effects are similar to trihexyphenidyl: dry mouth, blurred vision, constipation, and urinary retention are common. The cognitive risks in patients over 65 are significant — memory problems, confusion, and hallucinations can occur. Drink plenty of fluids, avoid overheating (benztropine impairs sweating), and avoid alcohol. If you are over 65, discuss the risks and benefits carefully with your neurologist, as current guidelines recommend against anticholinergic use in this age group.
Typical Dosing
Start 0.5mg at bedtime; increase by 0.5mg every 5-6 days. Usual dose 1-2mg twice daily. Maximum 6mg/day. Can also be given IV or IM for acute dystonic reactions (1-2mg).
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Dry mouth
- Blurred vision
- Constipation
- Urinary retention
- Drowsiness
- Confusion
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Cognitive impairment (especially in patients over 65)
- Confusion and delirium
- Angle-closure glaucoma
- Heat stroke (impaired sweating)
- Tardive dyskinesia (rare)
- Paralytic ileus
Contraindications
- Narrow-angle glaucoma
- Pyloric or duodenal obstruction
- Prostatic hyperplasia with urinary obstruction
- Myasthenia gravis
- Patients over 65 (relative contraindication — high cognitive risk)
Food Interactions
May be taken with food to reduce GI upset. Avoid alcohol, which intensifies sedation. The sedating properties may be useful if taken at bedtime for patients with insomnia.
Drug Interactions
The following interactions have been documented with Benztropine. Always inform your healthcare provider about all medications you are taking.
Two anticholinergic agents provide additive anticholinergic burden with no additional therapeutic benefit and greatly increased toxicity risk.
Clinical effects: Severe anticholinergic toxicity: cognitive impairment, confusion, urinary retention, paralytic ileus, hyperthermia, delirium.
Management: Never combine. Choose one anticholinergic only. Both are on the Beers Criteria as potentially inappropriate in elderly.
Both have anticholinergic properties. Amantadine has mild anticholinergic activity that is additive with benztropine.
Clinical effects: Increased anticholinergic effects: dry mouth, confusion, urinary retention, constipation, blurred vision.
Management: Use lowest effective doses. Monitor for cognitive changes especially in patients over 65.
How Benztropine Compares to Alternatives
Benztropine and trihexyphenidyl are the two anticholinergics available for PD. They have similar efficacy for tremor. Key differences: benztropine has additional antihistaminic activity (more sedating, may help with drooling and insomnia); trihexyphenidyl may be slightly less sedating. Neither is recommended by the 2025 AAN guideline as a preferred therapy. Benztropine has a unique role outside PD: it is the standard treatment for acute drug-induced dystonic reactions in emergency departments (1-2mg IV/IM). Both anticholinergics are listed on the Beers Criteria as potentially inappropriate for patients over 65.
When Is Benztropine Used by Disease Stage?
Same narrow indication as trihexyphenidyl: younger patients (under 60) with significant tremor that has not responded to levodopa, dopamine agonists, or MAO-B inhibitors. Not appropriate for patients over 65, those with cognitive impairment, or non-tremor-dominant PD. Has no role in mid-to-late stage PD where cognitive decline is a concern.
Additional Notes
Similar to trihexyphenidyl but with additional antihistaminic properties, which may cause more sedation. Use restricted to younger patients (<65) with tremor-dominant PD. Avoid in patients with cognitive impairment. Listed on the American Geriatrics Society Beers Criteria as potentially inappropriate in older adults. Also used in emergency departments for acute drug-induced dystonic reactions (1-2mg IV/IM).
Clinical Perspective
Benztropine, like trihexyphenidyl, belongs to an era of PD treatment that has largely passed. Its most common modern use is actually outside PD — in emergency departments for acute drug-induced dystonic reactions from antipsychotic medications. In PD, the same constraints apply as for all anticholinergics: appropriate only for a narrow population of younger, cognitively intact patients with refractory tremor. The antihistaminic sedation can occasionally be turned to advantage (nighttime dosing for patients with insomnia and tremor), but this is a minor consideration in the treatment algorithm.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson disease. Cochrane Database Syst Rev. 2003;(2):CD003735
- [2]American Geriatrics Society 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081
- [3]Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683
- [4]Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson disease. J Neurol Neurosurg Psychiatry. 2010;81(2):160-165
- [5]Tanner CM, Ostrem JL. Parkinson disease. N Engl J Med. 2024;391(5):442-452
Share this article